Skip to main content
. 2020 Nov 4;10:18999. doi: 10.1038/s41598-020-75886-w

Table 1.

Demographics, disease status, continuous antibiotic treatment and other therapeutics, and bacterial colonisation of CF patients with and without AF diagnosis in group 2. Patients with unknown AF diagnosis are not shown. *Chronic Pseudomonas infection defined by modified Leeds criteria31.

2016 2017
No AF diagnosis
(n = 2,591)		 One positive AF
(n = 439)		 At least two positive AF
(n = 571)		 P value
no AF vs. one AF
one AF vs. ≥ two AF
no AF vs. ≥ two AF		 No AF diagnosis
(n = 2,999)		 One positive AF
(n = 481)		 At least two positive AF
(n = 578)		 P value
no AF vs. one AF
one AF vs. ≥ two AF
no AF vs. ≥ two AF

Median age

(years, range)

 16.0 (0.0–78.8) 22.0 (1.0–73.0) 25.0 (3.0–74.0)

 < .0001

0.0003

 < .0001

 16.0 (0.0–79.0) 23.0 (0.0–70.0) 25.0 (6.0–75.0)

 < .0001

0.0013

 < .0001
Male (%) 53.4 50.8 47.3

0.3166

0.2684

0.0083

 52.3 54.9 50.4

0.2826

0.1408

0.4013

Median BMI percentile (range):

children

 32.0 (15.0–56.0) 24.0 (11.0–46.0) 27.0 (10.0–44.0)

0.0017

0.8511

0.0061

 33.0 (15.0–56.0) 26.0 (10.0–48.0) 26.0 (10.0–46.0)

0.0183

0.7625

0.0109
Median BMI (range): adults 21.1 (2.5–46.2) 21.4 (13.9–34.6) 20.9 (12.4- 30.8)

0.9722

0.1298

0.0417

 21.1 (13.3–46.1) 20.8 (15.0–37.9) 21.0 (13.6–32.0)

0.3455

0.5051

0.0356

Genotype

F508del homozygote (%)

F508del heterozygote (%)

Other genotype (%)

41.8

35.5

22.6

50.3

33.0

16.6

48.9

34.5

16.7

0.0014

0.8790

0.0014

42.5

35.8

21.7

47.3

37.9

14.8

47.7

35.4

17.0

0.0021

0.5309

0.0165
Pancreatic insufficiency (%) 95.9 95.4 96.0

0.6520

0.6805

0.9450

 95.2 96.5 96.2

0.2088

0.8150

0.2831
ABPA (%) 5.8 8.0 9.8

0.0714

0.3127

0.0004

 6.2 12.3 9.2

0.0714

0.3127

0.0004
CFRD (%) 16.4 20.3 24.9

0.0714

0.3127

0.0004

 17.2 20.6 27.0

0.0714

0.3127

0.0004
Liver disease (%) 28.8 38.7 41.9

 < .0001

0.3148

 < .0001

 26.4 35.1 38.2

 < .0001

0.2977

 < .0001
Arthritis and/or arthropathy (%) 3.9 4.6 6.3

0.4891

0.2286

0.0091

 3.3 5.0 6.8

0.0691

0.2286

0.0001
Therapy (%)
Continuous antibiotics 53.3 71.5 79.0

 < .0001

0.0061

 < .0001

 54.0 72.8 81.5

 < .0001

0.0007

 < .0001
Tobramycin (inhalative) 18.6 26.0 29.8

0.0003

0.1825

 < .0001

 18.5 26.2 31.0

 < .0001

0.0876

 < .0001
Colistin (inhalative) 23.4 33.5 40.3

 < .0001

0.0269

 < .0001

 22.1 39.1 41.7

 < .0001

0.3889

 < .0001
Aztreonam (inhalative) 11.5 21.2 24.5

 < .0001

0.2125

 < .0001

 12.4 20.2 23.9

 < .0001

0.1481

 < .0001
Bronchodilatators (inhalative) 82.4 88.4 93.9

0.0020

0.0020

 < .0001

 82.9 91.9 94.5

 < .0001

0.0957

 < .0001
Steroids 46.0 57.6 64.6

 < .0001

0.0235

 < .0001

 46.4 54.3 63.5

0.0014

0.0023

 < .0001
Inhalative steroids 33.0 45.8 51.5

 < .0001

0.0723

 < .0001

 33.4 43.7 52.4

 < .0001

0.0045

 < .0001
Oral steroids 8.1 11.6 13.0

0.0140

0.5207

0.0002

 8.9 9.6 12.3

0.6384

0.1597

0.0110
Antimycotics 10.5 13.2 12.1

0.0966

0.5921

0.2811

 11.1 12.9 13.7

0.2611

0.7106

0.0813
CFTR modulator ivacaftor 3.1 2.1 2.8

0.2338

0.4458

0.7189

 3.3 4.0 2.9

0.4409

0.3670

0.6836
CFTR modulator lumacaftor 4.6 10.7 14.2

 < .0001

0.0994

 < .0001

 8.5 12.5 16.8

0.0048

0.0495

 < .0001
Bacterial co-colonization with Pseudomonas aeruginosa, Staphylococcus aureus and non-tuberculous mycobacteria (%)
Pseudomonas aeruginosa (PA)* 36.7 52.2 62.2

 < .0001

0.0014

 < .0001

 36.5 54.3 63.5

 < .0001

0.0023

 < .0001
Mucoid PA 20.5 29.2 30.7

 < .0001

0.6083

 < .0001

 19.8 31.4 35.5

 < .0001

0.1623

 < .0001
multiresistant PA 11.7 16.2 21.2

0.0090

0.0439

 < .0001

 12.9 16.8 20.4

0.0188

0.1381

 < .0001
Staphylococcus aureus (SA) 65.7 69.0 67.6

0.1725

0.6310

0.3826

 64.8 70.5 68.9

0.0148

0.5683

0.0596
Non-tuberculous mycobacteria 1.2 3.2 8.8

0.0010

0.0003

 < .0001

 1.9 6.7 9.0

 < .0001

0.1599

 < .0001